Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

228 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Return to fertility after cessation of a continuous oral contraceptive.
Barnhart K, Mirkin S, Grubb G, Constantine G. Barnhart K, et al. Among authors: mirkin s. Fertil Steril. 2009 May;91(5):1654-6. doi: 10.1016/j.fertnstert.2008.02.122. Epub 2008 May 7. Fertil Steril. 2009. PMID: 18462723
SUBJECT(S): Participants in a phase 3 contraceptive trial who discontinued to become pregnant. INTERVENTION(S): Eligible subjects were contacted at 3 and 12 months after treatment discontinuation to determine if and when they had conceived. MAIN OUTCOME MEASURE(S
SUBJECT(S): Participants in a phase 3 contraceptive trial who discontinued to become pregnant. INTERVENTION(S): Eligible subje …
Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr.
Arslan M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Arslan M, et al. Among authors: mirkin s. Fertil Steril. 2005 Sep;84(3):555-69. doi: 10.1016/j.fertnstert.2005.02.053. Fertil Steril. 2005. PMID: 16169382 Review.
MAIN OUTCOME MEASURE(S): Ovarian response (peak serum estrogen levels, number of oocytes retrieved, quality of oocytes and embryos) and pregnancy outcome (clinical, delivery, and multiple pregnancy rates). RESULT(S): Controversies still exist regarding selection of …
MAIN OUTCOME MEASURE(S): Ovarian response (peak serum estrogen levels, number of oocytes retrieved, quality of oocytes and embryos) a …
Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells.
Navarro FJ, Mirkin S, Archer DF. Navarro FJ, et al. Among authors: mirkin s. Fertil Steril. 2003 Jun;79(6):1409-15. doi: 10.1016/s0015-0282(03)00350-9. Fertil Steril. 2003. PMID: 12798890
PATIENT(S): None. INTERVENTION(S): Ishikawa cells were cultured in vitro. Raloxifene, 17beta-E(2), and P at concentrations of 0.01, 0.1, and 1.0 microM were added to confluent cells. ...CONCLUSION(S): Raloxifene did not stimulate VEGF 121 and 165, whereas it …
PATIENT(S): None. INTERVENTION(S): Ishikawa cells were cultured in vitro. Raloxifene, 17beta-E(2), and P at concentrations of …
Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells.
Mirkin S, Wong BC, Archer DF. Mirkin S, et al. Fertil Steril. 2005 Aug;84(2):485-91. doi: 10.1016/j.fertnstert.2005.01.129. Fertil Steril. 2005. PMID: 16084894
PATIENT(S): None. INTERVENTION(S): MCF-7 and T47-D cells were cultured to 80% confluence in vitro. After 24 hours' incubation in serum-free media, 1.0, 0.1, and 0.01 microM of 17beta-estradiol, tibolone, 3alpha-hydroxytibolone and 3beta-hydroxytibolone were added to …
PATIENT(S): None. INTERVENTION(S): MCF-7 and T47-D cells were cultured to 80% confluence in vitro. After 24 hours' incubation …
Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells.
Archer DF, Navarro FJ, Leslie S, Mirkin S. Archer DF, et al. Among authors: mirkin s. Fertil Steril. 2004 Jan;81(1):165-70. doi: 10.1016/j.fertnstert.2003.05.028. Fertil Steril. 2004. PMID: 14711561
PATIENT(S): None. INTERVENTION(S): Ishikawa cells were cultured in vitro. After 24 hours' incubation in serum-free media, 1.0, 0.1, and 0.01 microM concentrations of E(2), levonorgestrel, medroxyprogesterone acetate, and norethindrone were added for a further 24 hou …
PATIENT(S): None. INTERVENTION(S): Ishikawa cells were cultured in vitro. After 24 hours' incubation in serum-free media, 1.0, …
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.
Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, Skouby SO, Smith L, Mirkin S, Constantine GD. Freeman EW, et al. Among authors: mirkin s. Contraception. 2012 May;85(5):437-45. doi: 10.1016/j.contraception.2011.09.010. Epub 2011 Dec 5. Contraception. 2012. PMID: 22152588 Review.
Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder.
Halbreich U, Freeman EW, Rapkin AJ, Cohen LS, Grubb GS, Bergeron R, Smith L, Mirkin S, Constantine GD. Halbreich U, et al. Among authors: mirkin s. Contraception. 2012 Jan;85(1):19-27. doi: 10.1016/j.contraception.2011.05.008. Epub 2011 Jul 13. Contraception. 2012. PMID: 22067793 Clinical Trial.
Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada.
Reid RL, Fortier MP, Smith L, Mirkin S, Grubb GS, Constantine GD. Reid RL, et al. Among authors: mirkin s. Contraception. 2010 Dec;82(6):497-502. doi: 10.1016/j.contraception.2010.06.002. Epub 2010 Jul 16. Contraception. 2010. PMID: 21074011
Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17beta-estradiol on thrombospondin-1 mRNA in Ishikawa cells.
Mirkin S, Archer DF. Mirkin S, et al. Fertil Steril. 2004 Jul;82(1):220-2. doi: 10.1016/j.fertnstert.2004.02.100. Fertil Steril. 2004. PMID: 15237017
Gene expression profiles and structural/functional features of the peri-implantation endometrium in natural and gonadotropin-stimulated cycles.
Mirkin S, Nikas G, Hsiu JG, Díaz J, Oehninger S. Mirkin S, et al. J Clin Endocrinol Metab. 2004 Nov;89(11):5742-52. doi: 10.1210/jc.2004-0605. J Clin Endocrinol Metab. 2004. PMID: 15531538 Clinical Trial.
228 results
Jump to page
Feedback